HepQuant Selected as a Semifinalist for 2018 InnoSTARS Competition to be Held in China
DENVER (May 9, 2018) — HepQuant, LLC, a Greenwood Village, Colo.-based company with a unique, patented and patent-pending technology for evaluating the liver in patients with chronic liver disease, announced today that the company has been named a semi-finalist for the 2018 InnoSTARS competition to be held in China later this year.
As a qualified preliminary winner in the Denver-area Healthcare and Biotechnology category, HepQuant has been invited to participate in a three-city China road trip with six other companies from Colorado.
“We are pleased to see HepQuant’s product innovations in the field of liver health diagnostics recognized here in Denver and are honored to be invited to the semifinal round in China,” noted Rick Whitcomb, Chief Operating Officer at HepQuant and the company’s presenter during last week’s Denver InnoSTARS competition.
InnoSTARS is a platform that connects U.S.-based technology companies with Chinese investors, corporates, and strategic partners. It is organized by the US China Innovation Alliance (UCIA) and China Science and Technology Exchange Center (CSTEC), and supported by the Ministry of Science and Technology of the P.R. China (MOST). This competition aims to provide U.S.-based technology companies a better understanding of the market opportunities available in China. Innosphere is the local co-organizer for this InnoSTARS Denver Preliminary round.
Headquartered in Greenwood Village, Colorado, HepQuant, LLC, is a privately-held, early-stage combination drug and in-vitro diagnostic company. HepQuant’s products are investigational combination drug and in-vitro diagnostic devices and have not yet been evaluated or reviewed by the US Food and Drug Administration (FDA) for commercial sale. They are currently available for investigational use via the FDA IDE application process. For additional information, visit www.hepquant.com.
Media Contact: Tom Kennedy
E: email@example.com | M: (720) 507-4164